Which produced greater weight reduction in clinical trials?

Phase II data published in the New England Journal of Medicine showed retatrutide produced up to ~24% mean body weight reduction at 48 weeks. Tirzepatide's SURMOUNT Phase III trials showed 15–22.5% over 72 weeks. Direct head-to-head trials have not been published as of 2026.

Is retatrutide FDA-approved?

No. As of 2026, retatrutide is in Phase III clinical trials. Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Research-grade retatrutide is available through research peptide suppliers for laboratory use only.

Are these peptides available for research use?

Research-grade versions of both compounds are available through research peptide suppliers for laboratory and analytical use only. They are not for human consumption. Use code SOL at Live Alpha Labs for 10% off. We may earn from qualifying purchases.

What role does the glucagon receptor play in retatrutide?

Glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure. This is the mechanism that differentiates retatrutide from dual agonists like tirzepatide, potentially contributing to the greater magnitude of body composition changes observed in early clinical data.

Which produced greater weight reduction in clinical trials?

Phase II data published in the New England Journal of Medicine showed retatrutide produced up to ~24% mean body weight reduction at 48 weeks. Tirzepatide's SURMOUNT Phase III trials showed 15–22.5% over 72 weeks. Direct head-to-head trials have not been published as of 2026.

Is retatrutide FDA-approved?

No. As of 2026, retatrutide is in Phase III clinical trials. Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Research-grade retatrutide is available through research peptide suppliers for laboratory use only.

Are these peptides available for research use?

Research-grade versions of both compounds are available through research peptide suppliers for laboratory and analytical use only. They are not for human consumption. Use code SOL at Live Alpha Labs for 10% off. We may earn from qualifying purchases.

What role does the glucagon receptor play in retatrutide?

Glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure. This is the mechanism that differentiates retatrutide from dual agonists like tirzepatide, potentially contributing to the greater magnitude of body composition changes observed in early clinical data.

Incretin research comparison

Tirzepatide vs Retatrutide: Dual vs Triple Agonist

Short answer: Tirzepatide activates two receptors (GIP + GLP-1). Retatrutide activates three (GIP + GLP-1 + glucagon). Phase II retatrutide data showed larger body composition changes than tirzepatide Phase III, but retatrutide lacks FDA approval and Phase III data as of 2026.

Disclosure: This page contains affiliate links. We may earn from qualifying purchases. See our full disclosure.

TirzepatideDual GIP/GLP-1

Receptors: GLP-1 + GIP (dual agonist)
Structure: 39-amino-acid peptide with C18 fatty diacid for albumin binding
Weight data: SURMOUNT Phase III — 15–22.5% mean reduction over 72 weeks
Approval: FDA-approved (Mounjaro, Zepbound) — extensive clinical dataset
Mechanism depth: Two-receptor incretin signaling without glucagon component
Research maturity: Phase III complete, real-world data accumulating

RetatrutideTriple GIP/GLP-1/Glucagon

Receptors: GLP-1 + GIP + Glucagon (triple agonist)
Structure: Single peptide activating all three incretin/glucagon pathways
Weight data: Phase II (NEJM) — up to ~24% mean reduction at 48 weeks
Approval: Not approved — Phase III trials ongoing (2026)
Mechanism depth: Glucagon adds hepatic lipid oxidation + energy expenditure
Research maturity: Phase II data; Phase III in progress (Eli Lilly)

Key Research Differences at a Glance

Criteria	Tirzepatide	Retatrutide
Receptors	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Max weight reduction (published)	22.5% (72wk Phase III)	~24% (48wk Phase II)
Glucagon pathway	No	Yes — hepatic lipid oxidation
FDA approval status	Approved (2 indications)	Phase III trials
Published research base	Extensive	Growing rapidly
Best for	Established dual-receptor studies	Triple-agonist / glucagon pathway research

Current research deal — use code SOL

10% off tirzepatide and retatrutide research compounds at Live Alpha Labs. Credit cards accepted. For research use only. We may earn from qualifying purchases.

Claim 10% off at Live Alpha →View Deals Hub

Related comparison

Tirzepatide vs Semaglutide

Related comparison

Tesofensine vs Tirzepatide

Shop profile

Retatrutide Research Profile

Shop profile

Tirzepatide Research Profile

Frequently Asked Questions

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor agonism in retatrutide enables hepatic lipid oxidation and energy expenditure pathways not activated by tirzepatide.

Tirzepatide vs Retatrutide: Dual vs Triple Agonist

Disclosure: This page contains affiliate links. We may earn from qualifying purchases. See our full disclosure.

Key Research Differences at a Glance

Criteria	Tirzepatide	Retatrutide
Receptors	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Max weight reduction (published)	22.5% (72wk Phase III)	~24% (48wk Phase II)
Glucagon pathway	No	Yes — hepatic lipid oxidation
FDA approval status	Approved (2 indications)	Phase III trials
Published research base	Extensive	Growing rapidly
Best for	Established dual-receptor studies	Triple-agonist / glucagon pathway research

Frequently Asked Questions